When people take nitrate medications for a long time, their body gets used to them and they stop working as well—this happens because the drugs cause cellular stress, damage the energy factories in cells, and make a key signaling molecule less responsive, so blood vessels don't open up as much anymore.

In human subjects with cardiovascular disease, chronic administration of a standardized nitrate (e.g., isosorbide mononitrate 60 mg/day) for 14 days compared to placebo, with vasodilatory response measured by flow-mediated dilation (FMD) before, during, and after treatment, and biomarkers of oxidative stress (e.g., 8-isoprostane), mitochondrial function (e.g., ATP production in platelets), and sGC activity (e.g., cGMP levels) assessed at each time point.

In a cohort of 100 chronic nitrate users (e.g., heart failure or angina patients), serial measurements of vasodilatory response (FMD), oxidative stress markers, mitochondrial function in circulating cells, and sGC activity over 6 months, with analysis of temporal relationships between declining FMD and rising biomarkers.

Comparison of oxidative stress, mitochondrial function, and sGC sensitivity in patients with documented clinical nitrate tolerance (e.g., loss of anti-anginal effect) versus matched nitrate-naïve patients with similar disease severity.

In human vascular smooth muscle cells, chronic exposure to a pharmacologically relevant concentration of a nitrate-derived NO donor (e.g., SNP 10 µM for 72h) induces measurable oxidative stress, mitochondrial depolarization, and reduced sGC responsiveness to NO, with vasodilatory capacity assessed via cGMP accumulation and calcium sensitivity.

In rats infused with isosorbide dinitrate (10 mg/kg/day via osmotic pump for 14 days), vascular reactivity of aortic rings to NO donors is measured alongside tissue levels of oxidative stress, mitochondrial complex activity, and sGC expression/activity.